SCHEMBL18990052

SCHEMBL18990052

[N-]=[N+]=N/C(=C/c1cc(Cl)ccc1Cl)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ ERCC5 P28715 2/20 0.35
▸ FEN1 P39748 2/20 0.35
▸ TSHR P16473 1/20 0.34
▸ CASP1 P29466 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ ERN1 O75460 1/20 0.33
▸ CYP2C19 P33261 2/20 0.33
▸ RAB9A P51151 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18990057 1.00 ALDH1A1 (0.38) ALDH1A1TP53ERCC5FEN1TSHR
SCHEMBL18990053 1.00 ALDH1A1 (0.38) ALDH1A1TP53ERCC5FEN1TSHR
SCHEMBL29062947 0.87 NPC1 (0.35) ALDH1A1SMN1; SMN2CYP2C19RAB9ACYP1A2
SCHEMBL18990256 0.83 POLB (0.34) ALDH1A1MEN1POLBKMT2ALMNA
SCHEMBL18990257 0.83 POLB (0.34) ALDH1A1MEN1POLBKMT2ALMNA
SCHEMBL30267904 0.83 POLB (0.34) ALDH1A1MEN1POLBKMT2ALMNA
SCHEMBL20535305 0.83 RHEB (0.40) ALDH1A1TP53CYP2C19CYP1A2MEN1
SCHEMBL20535306 0.83 RHEB (0.40) ALDH1A1TP53CYP2C19CYP1A2MEN1
SCHEMBL20535997 0.83 GRIK1 (0.34) ALDH1A1SMN1; SMN2ERN1CYP2C19RAB9A
SCHEMBL20535994 0.83 GRIK1 (0.34) ALDH1A1SMN1; SMN2ERN1CYP2C19RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-03-02 — — US disclosed
EP-3389664-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF Raze Therapeutics Inc. (US) 2018-10-24 — — EP disclosed
WO-2017106352-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF MTHFD2, MTHFD1, NUDT15 ALDH1A1 260/4885TP53 2424/4885ERCC5 590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback